Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available. Headquartered in Chalfont St. Giles, UK, GE Healthcare is a global leader in products and services for medical imaging, healthcare IT, diagnostic imaging agents, patient monitoring, drug discovery and protein separation. The company employs over 43,000 people and is a subsidiary of General Electric, one of the largest and most diversified companies in the world.

GE Healthcare comprises two main entities:

Headquartered in Waukesha, Wisconsin, USA, GE Healthcare Technologies is a US$12.1 billion business that provides medical imaging and information technologies, patient monitoring systems and healthcare services.

Headquartered in Little Chalfont, UK, GE Healthcare Bio-Sciences is a US$3 billion business that provides diagnostic imaging agents, drug discovery and protein separation systems.

GE Healthcare believes its key strategic benefit is that it is unique in having expertise in the complementary areas of medical diagnostics, diagnostic imaging, life sciences, IT, clinical systems and services, enabling it to capitalise on all current market opportunities, including:-

Medical trends - Disease management, molecular medicine, integrated diagnostics, non-invasive procedures and hospital digitalisation.
Technology trends - Miniaturisation, biotechnology and internet technology.
Market trends - Cost containment, consumerism and demographics.

In the future, GE Healthcare expects to benefit from these trends by focusing on three main technical themes to drive growth:-

Molecular imaging, which allows physicians to see disease at the molecular level. GE is working to commercialise diagnostic compounds such as Pittsburgh Compound B, which will be used with PET to spot the onset of neurological disorders and diseases such as breast cancer and heart failure, while tracking the impact of therapy. GE is the only company to offer contrast agents, hardware and software for molecular imaging.

Convergence between diagnostics and therapy. GE has partnerships under way with companies such as Eli Lilly and Roche to enhance product development in cardiology, cancer and neurology. The company's diagnostic technologies can help accelerate drug discovery using its information and process skills and the Abbott diagnostics acquisition will significantly enhance the company's presence in the diagnostics market. Over the next decade, GE expects US$250 billion in healthcare spending to shift from disease treatment to diagnosis.

Healthcare IT is critical to increasing the quality and lowering the cost of healthcare and is a growing market. A key strategy for GE is building an effective and broad-based electronic medical record (EMR). GE's position in the EMR market was enhanced through the acquisition of IDX and its collaboration with Intermountain Healthcare. GE believes sales for its healthcare IT business could grow by 10 to 15% a year for a long period of time.